Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders
暂无分享,去创建一个
[1] Ligang Zhou,et al. The Mechanism of Sodium-Glucose Cotransporter-2 Inhibitors in Reducing Uric Acid in Type 2 Diabetes Mellitus , 2023, Diabetes, metabolic syndrome and obesity : targets and therapy.
[2] T. Derks,et al. Continuous glucose monitoring for children with hypoglycaemia: Evidence in 2023 , 2023, Frontiers in Endocrinology.
[3] Beata Franczyk,et al. New Insights into the Use of Empagliflozin—A Comprehensive Review , 2022, Biomedicines.
[4] M. Veiga-da-Cunha,et al. Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients , 2022, Frontiers in Pediatrics.
[5] S. Gautam,et al. Molecular mechanism underlying impaired hepatic autophagy in glycogen storage disease type Ib. , 2022, Human Molecular Genetics.
[6] F. Bellanti,et al. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease , 2022, World journal of gastroenterology.
[7] M. Veiga-da-Cunha,et al. Repurposing of Empagliflozin as a Possible Treatment for Neutropenia and Inflammatory Bowel Disease in Glycogen Storage Disease Type Ib: A Case Report , 2022, Cureus.
[8] Passant E Moustafa,et al. Empagliflozin mitigates type 2 diabetes-associated peripheral neuropathy: a glucose-independent effect through AMPK signaling , 2022, Archives of Pharmacal Research.
[9] Z. Gaciong,et al. The overall benefits of empagliflozin treatment in adult siblings with glycogen storage disease type Ib: one year experience , 2022, Archives of medical science : AMS.
[10] C. Dionisi-Vici,et al. Glycogen storage diseases with liver involvement: a literature review of GSD type 0, IV, VI, IX and XI , 2022, Orphanet Journal of Rare Diseases.
[11] W. Tamborlane,et al. SGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance. , 2022, Pediatrics.
[12] Ning Liu,et al. Untargeted metabolomic profiling in a patient with glycogen storage disease Ib receiving empagliflozin treatment , 2022, JIMD reports.
[13] S. Grünert,et al. Two successful pregnancies and first use of empagliflozin during pregnancy in glycogen storage disease type Ib , 2022, JIMD reports.
[14] M. Veiga-da-Cunha,et al. Successful use of empagliflozin to treat neutropenia in two G6PC3‐deficient children: Impact of a mutation in SGLT5 , 2022, Journal of inherited metabolic disease.
[15] A. Ceriello,et al. Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin , 2022, Cellular and Molecular Life Sciences.
[16] H. Mizumoto,et al. Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire. , 2022, Genetics in medicine : official journal of the American College of Medical Genetics.
[17] K. Ejiri,et al. Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus , 2022, International journal of molecular sciences.
[18] J. Książyk,et al. Sodium‐glucose cotransporter type 2 channel inhibitor: Breakthrough in the treatment of neutropenia in patients with glycogen storage disease type 1b? , 2022, JIMD reports.
[19] R. Dalton,et al. Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre , 2022, Orphanet Journal of Rare Diseases.
[20] D. Lauro,et al. The molecular link between oxidative stress, insulin resistance, and type 2 diabetes: A target for new therapies against cardiovascular diseases. , 2021, Current opinion in pharmacology.
[21] M. Madkaikar,et al. SLGT2 Inhibitor Rescues Myelopoiesis in G6PC3 Deficiency , 2022, Journal of Clinical Immunology.
[22] B. Krämer,et al. Antifibrotic effects of low dose SGLT2 Inhibition with empagliflozin in comparison to Ang II receptor blockade with telmisartan in 5/6 nephrectomised rats on high salt diet. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[23] H. Malínská,et al. In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia , 2021, International journal of molecular sciences.
[24] Anqing Huang,et al. Mitophagy in Diabetic Cardiomyopathy: Roles and Mechanisms , 2021, Frontiers in Cell and Developmental Biology.
[25] S. Dib,et al. Use of a Sodium-Glucose Cotransporter 2 Inhibitor, Empagliflozin, in a Patient with Rabson-Mendenhall Syndrome , 2021, Hormone Research in Paediatrics.
[26] D. S. Froese,et al. Mitochondrial disease, mitophagy, and cellular distress in methylmalonic acidemia , 2021, Cellular and Molecular Life Sciences.
[27] G. Filippatos,et al. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction , 2021, Circulation.
[28] G. Filippatos,et al. Empagliflozin and Major Renal Outcomes in Heart Failure. , 2021, New England Journal of Medicine.
[29] H. Mizumoto,et al. Empagliflozin ameliorated neutropenia in a girl with glycogen storage disease Ib , 2021, Pediatrics international : official journal of the Japan Pediatric Society.
[30] M. Veiga-da-Cunha,et al. Crohn disease-like enterocolitis remission after empagliflozin treatment in a child with glycogen storage disease type Ib: a case report , 2021, Italian Journal of Pediatrics.
[31] R. Shrestha,et al. The Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non-Alcoholic Fatty Liver Disease , 2021, Cureus.
[32] Tiangang Li,et al. Autophagy in liver diseases: A review. , 2021, Molecular aspects of medicine.
[33] M. Rizzo,et al. The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart , 2021, International journal of molecular sciences.
[34] R. Loomba,et al. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk , 2021, Current Diabetes Reports.
[35] 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021. , 2020, Diabetes care.
[36] L. Altucci,et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin , 2020, Cardiovascular Diabetology.
[37] M. Baumgartner,et al. Untargeted plasma metabolomics identifies broad metabolic perturbations in glycogen storage disease type I , 2020, Journal of inherited metabolic disease.
[38] OUP accepted manuscript , 2021, European Heart Journal.
[39] A. Gastaldelli,et al. The role of the liver in the modulation of glucose and insulin in non alcoholic fatty liver disease and type 2 diabetes. , 2020, Current opinion in pharmacology.
[40] C. Borghi,et al. The new type 2 diabetes mellitus therapy: comparison between the two classes of drugs GLPR (glucagon-like peptide receptor) agonists and SGLT2 (sodium–glucose cotransporter 2) inhibitors , 2020, European heart journal supplements : journal of the European Society of Cardiology.
[41] C. Vargas,et al. Evidence that Oxidative Disbalance and Mitochondrial Dysfunction are Involved in the Pathophysiology of Fatty Acid Oxidation Disorders , 2020, Cellular and Molecular Neurobiology.
[42] P. Ponikowski,et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.
[43] M. Evans,et al. Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials , 2020, Diabetes Therapy.
[44] Krisy-Ann Thornby,et al. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease , 2020, The Annals of pharmacotherapy.
[45] S. Wortmann,et al. Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib , 2020, Orphanet Journal of Rare Diseases.
[46] I. Plastira,et al. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation. , 2020, Pharmacological research.
[47] R. Ferrigno,et al. Imbalanced cortisol concentrations in glycogen storage disease type I: evidence for a possible link between endocrine regulation and metabolic derangement , 2020, Orphanet Journal of Rare Diseases.
[48] M. Veiga-da-Cunha,et al. Treating neutropenia and neutrophil dysfunction in glycogen storage disease IB with an SGLT2-inhibitor. , 2020, Blood.
[49] A. Servais,et al. Infectious and digestive complications in glycogen storage disease type Ib: Study of a French cohort , 2020, Molecular genetics and metabolism reports.
[50] Hiroshi Ito,et al. Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet , 2020, Cardiovascular Diabetology.
[51] M. C. Casiraghi,et al. Proteobacteria Overgrowth and Butyrate-Producing Taxa Depletion in the Gut Microbiota of Glycogen Storage Disease Type 1 Patients , 2020, Metabolites.
[52] Irene J. Hoogeveen,et al. Dietary lipids in glycogen storage disease type III: A systematic literature study, case studies, and future recommendations , 2020, Journal of inherited metabolic disease.
[53] J. Vissing,et al. Titrating a modified ketogenic diet for patients with McArdle disease: A pilot study , 2020, Journal of inherited metabolic disease.
[54] M. Packer. SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action , 2020, Diabetes Care.
[55] P. Piirilä,et al. Beneficial Effects of Ketogenic Diet on Phosphofructokinase Deficiency (Glycogen Storage Disease Type VII) , 2020, Frontiers in Neurology.
[56] Takeshi Kimura,et al. Sodium-glucose Co-transporters-2 Inhibitors and Heart Failure: State of the Art Review and Future Potentials , 2020, International journal of heart failure.
[57] N. Tong,et al. Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway , 2019, Molecular and Cellular Endocrinology.
[58] J. Sadoshima,et al. Cardiomyopathy in obesity, insulin resistance and diabetes , 2020, The Journal of physiology.
[59] O. Elci,et al. Continuous Glucose Monitoring Systems: Are They Useful for Evaluating Glycemic Control in Children with Hyperinsulinism? , 2020, Hormone Research in Paediatrics.
[60] D. A. Weinstein,et al. Cornstarch requirements of the adult glycogen storage disease Ia population: A retrospective review , 2020, Journal of inherited metabolic disease.
[61] R. Fontes-Carvalho,et al. SGLT-2 Inhibitors in Heart Failure and Type-2 Diabetes: Hitting Two Birds with One Stone? , 2019, Cardiology.
[62] V. Demarco,et al. Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition. , 2019, Cellular signalling.
[63] Sang Hoon Kim,et al. Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy. , 2019, American journal of physiology. Renal physiology.
[64] Byung-Hoon Lee,et al. Hepatic upregulation of fetuin-A mediates acetaminophen-induced liver injury through activation of TLR4 in mice. , 2019, Biochemical pharmacology.
[65] D. Bali,et al. Liver fibrosis during clinical ascertainment of glycogen storage disease type III: a need for improved and systematic monitoring , 2019, Genetics in Medicine.
[66] Agnieszka Piwkowska,et al. AMPK signalling: Implications for podocyte biology in diabetic nephropathy , 2019, Biology of the cell.
[67] G. Bommer,et al. Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency , 2019, Proceedings of the National Academy of Sciences.
[68] C. Marra,et al. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis , 2019, BMJ Open.
[69] Marc P. Bonaca,et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.
[70] Michael S. Kelly,et al. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease , 2018, Postgraduate medicine.
[71] J. Kurtzberg,et al. Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor , 2019, Current opinion in hematology.
[72] E. Braunwald,et al. Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review. , 2018, Journal of the American College of Cardiology.
[73] C. Hetz,et al. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. , 2018, Journal of hepatology.
[74] John J. Mitchell,et al. Safety issues associated with dietary management in patients with hepatic glycogen storage disease. , 2018, Molecular genetics and metabolism.
[75] T. Kawaguchi,et al. High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection , 2018, Scientific Reports.
[76] P. Formisano,et al. Insulin-resistance in glycogen storage disease type Ia: linking carbohydrates and mitochondria? , 2018, Journal of Inherited Metabolic Disease.
[77] Amanda M Li,et al. Prolonged granulocyte colony stimulating factor use in glycogen storage disease type 1b associated with acute myeloid leukemia and with shortened telomere length , 2018, Pediatric hematology and oncology.
[78] Jun Ren,et al. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission , 2017, Redox biology.
[79] Qi-kuan Hu,et al. Lycium barbarum polysaccharide protects diabetic peripheral neuropathy by enhancing autophagy via mTOR/p70S6K inhibition in Streptozotocin-induced diabetic rats , 2017, Journal of Chemical Neuroanatomy.
[80] L. Henry,et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018, Nature Reviews Gastroenterology & Hepatology.
[81] J. A. Nogueira-Machado,et al. Cellular death, reactive oxygen species (ROS) and diabetic complications , 2018, Cell Death & Disease.
[82] S. Sarkar,et al. Dysregulation of autophagy as a common mechanism in lysosomal storage diseases , 2017, Essays in biochemistry.
[83] M. Chiang,et al. Activation of AMPK is neuroprotective in the oxidative stress by advanced glycosylation end products in human neural stem cells , 2017, Experimental cell research.
[84] Eva Dizin,et al. Dietary sodium induces a redistribution of the tubular metabolic workload , 2017, The Journal of physiology.
[85] C. Wanner. EMPA-REG OUTCOME: The Nephrologist's Point of View. , 2017, The American journal of cardiology.
[86] G. Shulman,et al. Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance. , 2017, Trends in pharmacological sciences.
[87] G. Sesti,et al. Uric Acid Is Associated With Inflammatory Biomarkers and Induces Inflammation Via Activating the NF-&kgr;B Signaling Pathway in HepG2 Cells , 2017, Arteriosclerosis, thrombosis, and vascular biology.
[88] M. Zeviani,et al. MtDNA-maintenance defects: syndromes and genes , 2017, Journal of Inherited Metabolic Disease.
[89] Y. Isaka,et al. Autophagy Inhibits the Accumulation of Advanced Glycation End Products by Promoting Lysosomal Biogenesis and Function in the Kidney Proximal Tubules , 2017, Diabetes.
[90] Ashutosh Kumar,et al. Adenosine Monophosphate-Activated Protein Kinase Abates Hyperglycaemia-Induced Neuronal Injury in Experimental Models of Diabetic Neuropathy: Effects on Mitochondrial Biogenesis, Autophagy and Neuroinflammation , 2017, Molecular Neurobiology.
[91] K. Park,et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE−/− mice fed a western diet , 2017, Diabetologia.
[92] S. Senniappan,et al. Flash glucose monitoring in children with congenital hyperinsulinism; first report on accuracy and patient experience , 2016 .
[93] D. Fitchett,et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. , 2016, Circulation.
[94] P. Groop,et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes , 2016, Diabetologia.
[95] K. Khunti,et al. Optimizing management of glycaemia. , 2016, Best practice & research. Clinical endocrinology & metabolism.
[96] Q. Anstee,et al. Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. , 2016, Annual review of pathology.
[97] Hiroshi Ito,et al. Postprandial hyperlipidemia as a potential residual risk factor. , 2016, Journal of cardiology.
[98] Laura J. McCloskey,et al. Model analysis of effect of canagliflozin (Invokana), a sodium-glucose cotransporter 2 inhibitor, to alter plasma 1,5-anhydroglucitol. , 2016, Clinica chimica acta; international journal of clinical chemistry.
[99] D. A. Weinstein,et al. Glycogen storage diseases: Diagnosis, treatment and outcome , 2016 .
[100] B. Zinman,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.
[101] G. Muscogiuri,et al. Glycogen storage disease type Ia (GSDIa) but not Glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation , 2015, Orphanet Journal of Rare Diseases.
[102] V. Vallon,et al. A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans , 2015, Naunyn-Schmiedeberg's Archives of Pharmacology.
[103] B. Zinman,et al. SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials , 2015, Diabetes & vascular disease research.
[104] J. Chou,et al. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes , 2015, Journal of Inherited Metabolic Disease.
[105] W. Chung,et al. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics , 2014, Genetics in Medicine.
[106] H. Yamada,et al. Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice , 2014, PloS one.
[107] J. Rosenstock,et al. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes , 2014, Diabetes Care.
[108] U. Broedl,et al. Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus , 2014, Circulation.
[109] Masayuki Yamamoto,et al. Possible involvement of nuclear factor erythroid 2-related factor 2 in the gene expression of Cyp2b10 and Cyp2a5 , 2014, Redox biology.
[110] G. Mithieux,et al. Glycogen storage disease type 1 and diabetes: learning by comparing and contrasting the two disorders. , 2013, Diabetes & metabolism.
[111] H. Nakano,et al. Serum uric acid in relation to serum 1,5-anhydroglucitol levels in patients with and without type 2 diabetes mellitus. , 2013, Clinical biochemistry.
[112] R. DeFronzo,et al. Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes , 2013, Diabetes Care.
[113] T. P. Neufeld,et al. ULK1 induces autophagy by phosphorylating Beclin-1 and activating Vps34 lipid kinase , 2013, Nature Cell Biology.
[114] P. Leung,et al. Inhibition of the sodium glucose co‐transporter‐2: its beneficial action and potential combination therapy for type 2 diabetes mellitus , 2013, Diabetes, obesity & metabolism.
[115] Gabi Kastenmüller,et al. Early Metabolic Markers of the Development of Dysglycemia and Type 2 Diabetes and Their Physiological Significance , 2013, Diabetes.
[116] S. Kume,et al. Sirtuins and renal diseases: relationship with aging and diabetic nephropathy , 2012, Clinical science.
[117] Sarika Gupta,et al. Gout, anemia, and hepatomegaly in a young man with glycogen storage disease. , 2012, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[118] N. Calcutt,et al. Impaired adenosine monophosphate-activated protein kinase signalling in dorsal root ganglia neurons is linked to mitochondrial dysfunction and peripheral neuropathy in diabetes. , 2012, Brain : a journal of neurology.
[119] M. Emoto,et al. Fetuin-A: a multifunctional protein. , 2011, Recent patents on endocrine, metabolic & immune drug discovery.
[120] K. Bhattacharya. Dietary dilemmas in the management of glycogen storage disease type I , 2011, Journal of Inherited Metabolic Disease.
[121] R. Henry,et al. SGLT2 inhibition — a novel strategy for diabetes treatment , 2010, Nature Reviews Drug Discovery.
[122] C. Kahn,et al. Myeloid Cell-Restricted Insulin Receptor Deficiency Protects Against Obesity-Induced Inflammation and Systemic Insulin Resistance , 2010, PLoS genetics.
[123] F. Lang,et al. In vivo stimulation of AMP-activated protein kinase enhanced tubuloglomerular feedback but reduced tubular sodium transport during high dietary NaCl intake , 2010, Pflügers Archiv - European Journal of Physiology.
[124] R. Santer,et al. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[125] M. Shimabukuro. Cardiac adiposity and global cardiometabolic risk: new concept and clinical implication. , 2009, Circulation journal : official journal of the Japanese Circulation Society.
[126] Shukun Yu. The anhydrofructose pathway of glycogen catabolism , 2008, IUBMB life.
[127] A. Maiorana,et al. Adipose Tissue: A Metabolic Regulator. Potential Implications for the Metabolic Outcome of Subjects Born Small for Gestational Age (SGA). , 2007, The review of diabetic studies : RDS.
[128] M. Vorgerd,et al. Treatment of glycogenosys type V (McArdle disease) with creatine and ketogenic diet with clinical scores and with 31P-MRS on working leg muscle. , 2007, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.
[129] K. Gempel,et al. Treatment of glycogenosis type V with ketogenic diet , 2005, Annals of neurology.
[130] E. Feldman,et al. Oxidative stress in the pathogenesis of diabetic neuropathy. , 2004, Endocrine reviews.
[131] J. Duby,et al. Diabetic neuropathy: an intensive review. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[132] Y. Akanuma,et al. Urinary excretion of 1,5-anhydro-D-glucitol accompanying glucose excretion in diabetic patients , 1988, Diabetologia.
[133] G. Andria,et al. Crohn's‐like ileo‐colitis in patients affected by glycogen storage disease Ib: two years’follow‐up of patients with a wide spectrum of gastrointestinal signs , 2003, Acta paediatrica.
[134] G. Andria,et al. Crohn's-like ileo-colitis in patients affected by glycogen storage disease Ib: two years’follow-up of patients with a wide spectrum of gastrointestinal signs , 2003 .
[135] J. Leonard,et al. Guidelines for management of glycogen storage disease type I – European Study on Glycogen Storage Disease Type I (ESGSD I) , 2002, European Journal of Pediatrics.
[136] R. Schmidt,et al. Neurofilaments in diabetic neuropathy. , 2002, International review of neurobiology.
[137] I. Obrosova. How does glucose generate oxidative stress in peripheral nerve? , 2002, International review of neurobiology.
[138] J. Leonard,et al. Consensus guidelines for management of glycogen storage disease type 1b – European Study on Glycogen Storage Disease Type 1 , 2002, European Journal of Pediatrics.
[139] J. Leonard,et al. Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European Study on Glycogen Storage Disease Type 1 , 2002, European Journal of Pediatrics.
[140] A. Aljada,et al. Insulin Inhibits NFκB and MCP-1 Expression in Human Aortic Endothelial Cells , 2001 .
[141] J. Leonard,et al. Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European Study on Glycogen Storage Disease type I. , 2000, The Journal of pediatrics.
[142] I. Gérin,et al. A gene on chromosome 11q23 coding for a putative glucose- 6-phosphate translocase is mutated in glycogen-storage disease types Ib and Ic. , 1998, American journal of human genetics.
[143] H. Akanuma,et al. Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body. , 1992, The American journal of physiology.
[144] R. Mahler. Glycogen storage diseases , 1969 .
[145] A. Sols,et al. The non-competitive inhibition of brain hexokinase by glucose-6-phosphate and related compounds. , 1954, The Journal of biological chemistry.